Champions Oncology, Inc. (CSBR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-13.9%

$4.14

vs $4.81 price

Levered DCF

$0.08

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-0.28

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-74.5×	21.03×	-8.98×	-12.46×	185.06×	388.77×	-42.89×	803.54×
P/B	20.93×	25.89×	-34.53×	14.2×	11.14×	18.98×	17.93×	46.01×
P/S	1.39×	1.72×	1.31×	1.22×	2.06×	3.44×	2.85×	3.8×
EV / EBITDA	183.22×	15×	-12.96×	-21.28×	46.07×	94.13×	-114.18×	113.87×
Gross margin	48.0%	50.1%	41.4%	45.2%	51.9%	47.7%	47.1%	47.3%
Operating margin	-1.9%	8.5%	-13.8%	-8.3%	1.2%	0.9%	-6.0%	1.0%
Net margin	-2.0%	8.3%	-14.5%	-9.9%	1.1%	0.9%	-6.5%	0.5%
Current ratio	0.96×	0.94×	0.63×	0.9×	1.13×	1.13×	1.1×	0.99×
Debt / equity	1.15×	1.62×	-3.9×	1.85×	1.04×	1.29×	0.74×	0.01×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-29.8%	124.6%	382.3%	-115.1%	6.0%	4.9%	-41.0%	5.7%
Return on invested capital	-13.3%	48.6%	-116.2%	-32.3%	3.0%	1.8%	-21.2%	4.6%
Return on assets	-4.4%	14.5%	-27.8%	-15.5%	1.5%	1.3%	-10.1%	1.1%
Free cash flow yield	-6.1%	7.2%	-10.6%	1.6%	4.1%	-3.5%	0.7%	1.0%
Earnings yield	-1.4%	4.8%	-11.1%	-8.1%	0.5%	0.3%	-2.3%	0.1%
Enterprise value	$82.1M	$94M	$70.5M	$64.3M	$101.8M	$145.9M	$86.9M	$99.7M
Net debt / EBITDA	-0.8×	-0.59×	-0.88×	0.5×	0.21×	3.17×	5.97×	-3.68×
Cash conversion cycle (days)	-1	17	-3	-12	26	30	-13	-13